Sai Life Sciences IPO Opened Today - Day 1 Live Updates, Key Highlights, Subscription Status, and Insights
Sai Life Sciences Limited is a research, development, and manufacturing company specializing in small-molecule new chemical entities. It launched its initial public offering (IPO) Today, December 11, 2024.
Sai Life Sciences IPO Details
- The Sai Life Sciences IPO is a book-built issue totalling ₹3,042.62 crores. The offering consists of a fresh issue of 1.73 crore shares amounting to ₹950.00 crores and an offer for sale of 3.81 crore shares totalling ₹2,092.62 crores.
- The IPO opens for subscription on December 11, 2024, and closes on December 13, 2024.
- The allotment of shares for the Sai Life Sciences IPO is expected to be finalized on Monday, December 16, 2024.
- The shares are scheduled to be listed on the BSE and NSE, with a tentative listing date set for Wednesday, December 18, 2024.
- The IPO price band is set between ₹522 and ₹549 per share.
- For retail investors, the minimum application size is 27 shares per lot.
- For small non-institutional investors (sNII), the minimum investment size is 14 lots (378 shares), requiring an investment of ₹2,07,522.
- For large non-institutional investors (bNII), it is 68 lots (1,836 shares), requiring an investment of ₹1,007,964.
Investor Category Shares Offered
|
Investor Category |
(%) |
|
Anchor Investor |
30 |
|
QIB |
20 |
|
NII (HNI) |
15 |
|
Retail |
35 |
Utilization of IPO Proceeds
The company plans to utilize the Net Proceeds for two primary objectives: to repay or prepay, in full or in part, certain outstanding borrowings and to fund general corporate purposes.
Sai Life Sciences IPO Day 1 Subscription Status
(December 11, 2024, 12:40:00 PM)
On the opening day of bidding, the Sai Life Sciences IPO recorded a subscription level of 0.06 times the total shares available.
- The Non-Institutional Investors (NIIs) subscribed to 0.05 times their allocated quota,
- The Retail Investors segment showed a promising response, with subscriptions reaching 0.09 times their allocation.
- In contrast, the Qualified Institutional Buyers (QIBs) segment, although participating, registered a subscription rate of 0.00 times.
Sai Life Sciences Business Overview
Established in January 1999, Sai Life Sciences Limited specializes in the research, development, and manufacturing of small-molecule new chemical entities. The company provides customized services to biotech companies and global pharmaceutical firms.
During the financial year 2024 and as of September 30, 2024, Sai Life Sciences served over 280 innovator pharmaceutical companies, including more than 230 in September alone. Notably, the company collaborated with 18 of the top 25 pharmaceutical companies by revenue in the calendar year 2023. Its services are offered across key markets, including the US, the UK, Europe, and Japan.
The company’s business development team comprises 16 skilled and experienced professionals, strategically positioned with six in the US, nine in the UK and Europe, and one in Japan.
Sai Life Sciences Financial Highlights:
- Revenue increased by 20% from Rs. 1,245 crore in FY23 to Rs. 1,494 crore in FY24.
- Profit after tax (PAT) rose by 729% between the financial year ending March 31, 2024 and March 31, 2023, from Rs. 9.99 crore to Rs. 82.81 crore, respectively.
Key Ratios
|
Years |
FY24 |
|
ROE |
11.79% |
|
ROCE |
15.96% |
|
EBITDA Margin |
20.48% |
|
PAT Margin |
5.65% |